In the preceding calendar year the mean number of UTIs was 2.8, (range: 2 - 5).
During the treatment year, 16 (32%) of the placebo group, 10 (20%; p<0.05) in the juice group and 9 (18%), (p<0.05) in the tablet group experienced at least 1 UTI.
During the year following the study, the mean number of UTIs was 0.72 in the placebo group, 0.30 in the juice group, (p<0.05), and 0.39 in the tablet group, (p<0.05).
In terms of side effects 2 patients in the placebo group experienced headache and 2 patients experienced mild nausea. In the juice group, 3 patients experienced reflux. In the tablet group 4 patients experienced mild nausea and 1 experienced increased frequency of bowel movements. Eight patients complained about the size of the tablets.
Monthly compliance data showed that the compliance with the regimes was lowest in the juice group, dropping below 80% during 5 of the 12 months.